경구 백신 시장 : 백신 유형별, 질환별, 연령층별, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Oral Vaccine Market is projected to grow by USD 7.34 billion at a CAGR of 8.43% by 2032.

Oral Vaccine Market Executive Introduction

The oral vaccine market sits at the intersection of infectious disease control, mucosal immunology, outbreak preparedness, and scalable immunization delivery. Oral vaccines are valued because they can stimulate immune responses at mucosal surfaces, simplify administration compared with injectable products, and support mass vaccination campaigns in settings where trained vaccinators, sterile injection supplies, and clinic-based delivery capacity are constrained.

Commercial and public health demand is anchored by established products such as oral polio vaccine, rotavirus vaccines, oral cholera vaccines, and oral typhoid vaccines. The category is also gaining strategic attention as governments, multilateral buyers, and manufacturers pursue thermostable formulations, improved supply security, and next-generation platforms that can reduce logistical friction across routine immunization, travel medicine, and emergency response.

Transformative Shifts in the Oral Vaccine Landscape

The oral vaccine landscape is shifting from product availability toward program resilience, equity of access, and rapid outbreak response. Global experience with oral polio vaccine demonstrates the value of easy administration at scale, while also showing the importance of high coverage, surveillance, and careful strain selection to reduce vaccine-derived poliovirus risk in under-immunized communities.

Rotavirus and cholera vaccination programs are accelerating the focus on affordability, cold-chain optimization, and supply diversification. The global cholera resurgence reported by the World Health Organization has intensified demand for oral cholera vaccine stockpiles, while rotavirus vaccine adoption in national immunization schedules continues to support pediatric disease prevention in low- and middle-income countries.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical accelerator across oral vaccine discovery, development, manufacturing, and post-market monitoring. In research, AI-enabled modeling can help prioritize antigens, predict immune epitopes, assess strain evolution, and support formulation screening for stability and mucosal delivery performance. These applications are most valuable when paired with validated laboratory assays, clinical evidence, and regulatory-grade quality systems.

AI also strengthens demand forecasting, pharmacovigilance signal detection, cold-chain planning, and outbreak allocation decisions. For oral vaccines used in emergency campaigns, such as oral cholera vaccine and oral polio vaccine, predictive analytics can help public health agencies align stockpiles, distribution timing, and population targeting with epidemiological risk while maintaining human oversight and transparent governance.

Key Regional Insights for Oral Vaccines

Asia-Pacific is a major growth arena for oral vaccines because of large birth cohorts, high population density, and continued investment in routine immunization. India and China influence global supply and demand through domestic manufacturing scale, national immunization priorities, and expanding biotechnology capabilities, while Southeast Asian markets benefit from donor-supported vaccination, regional disease surveillance, and continued focus on rotavirus, cholera, typhoid, and polio prevention.

North America and Europe are characterized by mature regulatory systems, travel vaccine demand, advanced pharmacovigilance, and strong clinical development infrastructure. In North America, oral vaccine demand is shaped by traveler protection, outbreak readiness, and evidence-based immunization guidance, while Europe supports clinical quality standards, centralized regulatory coordination, and public-sector procurement discipline. Latin America remains important for rotavirus vaccine uptake, outbreak preparedness, and public-sector procurement, supported by regional experience in immunization campaigns and diarrheal disease control. The Middle East increasingly links immunization planning with humanitarian response, migration, pilgrimage health security, and regional cold-chain modernization. Africa represents one of the most consequential demand centers for oral polio vaccine, rotavirus vaccines, and oral cholera vaccines due to disease burden, emergency campaigns, cross-border transmission risks, and the strategic role of WHO-, UNICEF-, and Gavi-supported programs.

Key Group Insights Across Major Economic Blocs

ASEAN markets are advancing oral vaccine access through immunization strengthening, local regulatory cooperation, and growing attention to cholera, typhoid, and pediatric diarrheal disease prevention. The GCC combines high-income health systems with travel, migration, and pilgrimage-related health security needs, supporting demand for targeted oral vaccine preparedness, traveler protection, and emergency response coordination.

The European Union and G7 shape standards for clinical evidence, vaccine safety monitoring, financing, procurement quality, and manufacturing oversight, reinforcing the role of transparent regulatory pathways and post-market surveillance in oral vaccine adoption. NATO countries increasingly view vaccine supply security, stockpile planning, and resilient logistics as part of broader health security and civil preparedness. BRICS nations are especially influential because China, India, Brazil, Russia, and South Africa combine large populations, public procurement power, expanding vaccine manufacturing capacity, and technology-transfer priorities that can affect global oral vaccine availability and access.

Key Country Insights in Leading Oral Vaccine Markets

The United States and Canada emphasize stringent regulatory review, traveler vaccination, clinical innovation, immunization safety monitoring, and outbreak readiness, while Mexico and Brazil support regional demand through public immunization programs, pediatric vaccine adoption, and disease surveillance. In Europe, the United Kingdom, Germany, France, Italy, and Spain contribute advanced research capacity, procurement discipline, clinical trial infrastructure, and regulatory alignment through European systems, while Russia maintains domestic vaccine production capabilities and strategic immunization programs.

China and India are central to oral vaccine manufacturing, scale-up economics, and national disease control priorities, with both countries playing influential roles in pediatric immunization, outbreak response, and supply continuity. Japan, Australia, and South Korea add high-quality clinical research, advanced cold-chain infrastructure, strong regulatory oversight, and regional health security leadership, strengthening Asia-Pacific's role in next-generation oral vaccine development and deployment.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize resilient supply chains, diversified antigen and formulation pipelines, and manufacturing partnerships that can respond to both routine immunization demand and emergency outbreak surges. Investments in thermostable oral vaccine technologies, packaging efficiency, strain surveillance, and lower-cost production can improve access in markets where cold-chain limitations and campaign logistics remain persistent barriers.

Organizations should also strengthen evidence generation for mucosal immunity, duration of protection, safety in target age groups, co-administration with routine vaccines, and real-world effectiveness. Strategic alignment with WHO prequalification pathways, national immunization technical advisory groups, donor procurement requirements, regulatory quality expectations, and digital pharmacovigilance systems will be essential for credible market entry and sustainable adoption.

Research Methodology

This executive summary is developed through a structured synthesis of verified public health, regulatory, and market-relevant sources, including WHO guidance, UNICEF and Gavi procurement context, national immunization program practices, regulatory agency frameworks, peer-reviewed evidence, and established vaccine safety principles. The analysis emphasizes factual signals rather than speculative market claims, sizing assumptions, or forecast-based conclusions.

The methodology evaluates product categories, disease burden drivers, regional immunization dynamics, procurement mechanisms, regulatory pathways, technology trends, and supply-chain constraints. Insights are cross-checked for consistency across public health priorities, commercial feasibility, and operational realities affecting oral polio, rotavirus, cholera, and typhoid vaccine deployment.

Conclusion

Oral vaccines remain a critical segment of global immunization because they combine public health impact with operational simplicity. Their value is most visible in pediatric disease prevention, mass campaigns, outbreak response, travel medicine, and settings where injectable delivery is harder to sustain at scale.

The future of the oral vaccine market will be shaped by supply reliability, next-generation mucosal delivery science, AI-supported development, and policy alignment across countries and procurement bodies. Organizations that invest in evidence, affordability, manufacturing resilience, quality systems, and equitable access will be best positioned to support this evolving market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Oral Vaccine Market, by Vaccine Type

• 7.1. Conjugate Vaccines
• 7.2. Inactivated Vaccines
  • 7.2.1. Whole-Cell Inactivated
  • 7.2.2. Toxoid-Based
• 7.3. Live Attenuated Vaccines
  • 7.3.1. Bacterial
  • 7.3.2. Viral
• 7.4. Mrna Vaccines
• 7.5. Subunit Vaccines
  • 7.5.1. Protein Subunit
  • 7.5.2. Polysaccharide Subunit

8. Oral Vaccine Market, by Disease Indication

• 8.1. Influenza
• 8.2. Norovirus
• 8.3. Poliovirus
• 8.4. Rotavirus

9. Oral Vaccine Market, by Age Group

• 9.1. Adult
• 9.2. Geriatric
• 9.3. Pediatric

10. Oral Vaccine Market, by Distribution Channel

• 10.1. Online
• 10.2. Offline

11. Oral Vaccine Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Oral Vaccine Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Oral Vaccine Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. AstraZeneca plc
• 15.2. Bharat Biotech International Limited
• 15.3. Biological E. Limited
• 15.4. Cadila Healthcare Limited
• 15.5. Emergent BioSolutions Inc.
• 15.6. GlaxoSmithKline plc
• 15.7. Indian Immunologicals Limited
• 15.8. Johnson & Johnson
• 15.9. Merck & Co., Inc.
• 15.10. Novavax, Inc.
• 15.11. Oramed Pharmaceuticals Inc.
• 15.12. Panacea Biotec Limited
• 15.13. Pfizer Inc.
• 15.14. Sanofi S.A.
• 15.15. Serum Institute of India Private Limited
• 15.16. Valneva SE
• 15.17. Vaxart, Inc.